Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Ltd., commonly known as Sun Pharma, is a leading global pharmaceutical company headquartered in India. Established in 1993, the company has grown to become one of the largest specialty generic pharmaceutical manufacturers in the world, with a strong presence in North America, Europe, and emerging markets. Sun Pharma focuses on a diverse range of therapeutic areas, including cardiology, psychiatry, neurology, and dermatology. Its core products encompass a wide array of generic medications, specialty pharmaceuticals, and over-the-counter products, distinguished by their high quality and affordability. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of innovative therapies. With a commitment to research and development, Sun Pharma has positioned itself as a key player in the global pharmaceutical landscape, recognised for its excellence in manufacturing and a strong market presence.
DitchCarbon Score
How does Sun Pharmaceutical Industries's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sun Pharmaceutical Industries's score of 52 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sun Pharmaceutical Industries's reported carbon emissions
In 2024, Sun Pharmaceutical Industries, headquartered in India, reported significant carbon emissions, with Scope 1 emissions totalling approximately 111,175,000 kg CO2e and Scope 2 emissions reaching about 237,766,000 kg CO2e. This data reflects their commitment to transparency in environmental impact reporting. Globally, in 2024, the company recorded Scope 1 emissions of about 45,606,090 kg CO2e, Scope 2 emissions of approximately 323,237,430 kg CO2e, and Scope 3 emissions amounting to around 379,788,320 kg CO2e. The Scope 3 emissions included categories such as purchased goods and services, which accounted for about 236,932,260 kg CO2e. Sun Pharmaceutical has set ambitious targets to reduce its carbon footprint, aiming for a 35% reduction in both Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. This commitment is part of their broader sustainability strategy, which includes ongoing efforts to enhance energy efficiency and reduce overall emissions intensity. The company’s emissions data is not cascaded from any parent organisation, indicating that these figures are independently reported. Sun Pharmaceutical's proactive approach to climate commitments positions it as a responsible player in the pharmaceutical industry, aligning with global sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sun Pharmaceutical Industries is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
